Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells

The clinical success of EGFR inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance. Here, we show that inhibition of SREBP increase gefitinib sensitivity in vitro and in vivo. Interference of SREBP1 binding partner MARVELD1 potentiate the therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiajin, Yan, Hui, Zhao, Li, Jia, Wenzhi, Yang, Hao, Liu, Liu, Zhou, Xiang, Miao, Ping, Sun, Xiaoguang, Song, Shaoli, Zhao, Xiaoping, Liu, Jianjun, Huang, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239560/
https://www.ncbi.nlm.nih.gov/pubmed/27447558
http://dx.doi.org/10.18632/oncotarget.10721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239560/
https://www.ncbi.nlm.nih.gov/pubmed/27447558
http://dx.doi.org/10.18632/oncotarget.10721

Ejemplares similares